Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02454179 | Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma(KEYNOTE147) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01581970 | Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer | completed | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 11, 2019 |
| clinicaltrials |
| NCT03830385 | Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck | unknown | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT00894413 | A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02216916 | Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy | unknown | Phase 2 | 49 | Yonsei UniversityOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT03843671 | Hyperbaric Radiation Sensitization of Head and Neck Cancers | unknown | Phase 2 | 400 | National Baromedical ServicesOTHER | 2 | Feb 18, 2019 | clinicaltrials |
| NCT03121313 | Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ | unknown | Phase 2 | 68 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01696955 | Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | terminated | Phase 2 | 1 | HiberCell, Inc.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03744208 | SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Shi YuankaiUNKNOWN | 0 | Nov 16, 2018 | clinicaltrials |
| NCT03096184 | A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers | unknown | Phase 2 | 38 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01941992 | Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients(ROSAM) | completed | Phase 2 | 120 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT02507154 | Reactivating NK Cells in Treating Refractory Head and Neck Cancer(NKEXPHNC) | unknown | Phase 1 / Phase 2 | 31 | National University Hospital, SingaporeOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01218048 | ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 40 | Robert FerrisOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT02048020 | Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer | completed | Phase 2 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | terminated | Phase 2 | 157 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 24, 2018 | clinicaltrials |
| NCT01204099 | Study of PX-866 and Docetaxel in Solid Tumors | completed | Phase 1 / Phase 2 | 223 | Cascadian Therapeutics Inc.INDUSTRY | 2 | May 16, 2018 | clinicaltrials |
| NCT01316757 | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | completed | Phase 2 | 24 | Fox Chase Cancer CenterOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT03424291 | A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 6, 2018 | clinicaltrials |
| NCT00408694 | Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01488318 | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | terminated | Phase 2 | 21 | Julie E. Bauman, MD, MPHOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT01051791 | Phase II Study of RAD001 Head and Neck Cancer | terminated | Phase 2 | 13 | Julie E. Bauman, MD, MPHOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01221753 | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study | terminated | Phase 2 | 7 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT03356587 | A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy | unknown | Phase 2 | 32 | Seoul National University HospitalOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT01237483 | Reirradiation and Erbitux in the HNSCC | completed | Phase 2 | 50 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT01542931 | TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 256 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01733823 | DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole | completed | Phase 1 / Phase 2 | 31 | Danish Head and Neck Cancer GroupNETWORK | 1 | Jul 28, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT03196869 | the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer | unknown | Phase 2 | 128 | Guiyang Medical UniversityOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01528163 | Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(RACATREX) | completed | Phase 2 | 101 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 2 | Jun 14, 2017 | clinicaltrials |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT02639858 | Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC | unknown | Phase 2 | 31 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 1, 2017 | clinicaltrials |
| NCT03117257 | Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN | unknown | Phase 2 | 144 | Guiyang Medical UniversityOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 2 | Apr 14, 2017 | clinicaltrials |
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01256385 | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy(MAESTRO HN) | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Mar 27, 2017 | clinicaltrials |
| NCT00095628 | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2017 | clinicaltrials |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | terminated | Phase 1 / Phase 2 | 3 | Innate PharmaINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT02985255 | Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue | unknown | Phase 2 | 30 | HealthCare Global Enterprise Ltd.INDUSTRY | 1 | Dec 7, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Sep 12, 2019source: clinicaltrials